Hema Now | Episode 28
In this episode of Hema Now, Pieter Sonneveld, Chair of the European Myeloma Network (EMN) and a leading voice in haematology, discusses how groundbreaking research and collaborative trials, like PERSEUS and CEPHEUS, are redefining standards of care in multiple myeloma. From the importance of early diagnosis to the evolving role of minimal residual disease testing, this conversation offers a forward-looking perspective on what’s next for patients and clinicians alike.
Pieter Sonneveld is a Professor of Hematology at Erasmus MC in Rotterdam, the Netherlands.
He earned his medical degree from Erasmus University Rotterdam, the Netherlands, and went on to complete his PhD at the University of Leiden, the Netherlands. He currently chairs both the HOVON Multiple Myeloma Working Group and the European Myeloma Network (EMN), coordinating numerous international clinical trials.
Timestamps
00:00 – Introduction
01:36 – Initial interest in multiple myeloma
03:24 – Treatment landscape
05:25 – Minimal residual disease
08:20 – European Myeloma Network (EMN)
11:04 – Overview of the PERSEUS trial
14:37 – Overview of the CEPHEUS trial
17:45 – The future of myeloma care
20:38 – Pieter’s three wishes for healthcare
